Recent news
and insights
NTRK gene fusions, TRK inhibitors and testing approaches BluePrint
A variety of topics are covered including, overview of gene fusions and role as oncogenic drivers, detection approaches available, NTRK family and NTRK gene fusions...
The role of PARP inhibition in clinical practice
Understand why, where and how PARP inhibitors work in clinical practice, and look into the future of targeting DDR with this interactive, free to access e-learning course.
Overview of cancers with NTRK Gene Fusions and importance of testing
Information on TRK fusion proteins as a potential therapeutic target for selected patients across multiple tumour types.
Management of Skin Toxicities from MKI Therapies (Recently Updated)
Comprehensive resource providing information on the management of multikinase inhibitor-associated skin toxicities.
ESMO OncologyPRO resource on PARP inhibition and DNA Damage response (DDR)
Information on PARP inhibition and DNA Damage Response (DDR) as therapeutic targets across multiple tumour types.
Understand the mechanism of action of PARP inhibitors and targeting DNA Damage Response (DDR): A short video
This short video succinctly explains the concept of DDR, including the role of Homologous Recombination Repair (HRR) in DNA repair and the impact of BRCA1 and BRCA2 mutations
The CONNECTs News
-
Antibody-drug conjugates in urothelial cancer
-
GI CONNECT Update from WCGIC 2020
-
HCC CONNECT Update from WCGIC 2020
-
Overview of treatments for advanced HCC
-
NTRK CONNECT Update from ASCO 2020
-
GU Nurses CONNECT Update from ASCO 2020
-
Recent developments in the treatment of DLBCL
-
NET CONNECT Scientific Projects presented at ENETS 2020
-
Molecular subtypes that exist in paediatric and adult sarcomas. This includes a spotlight on the potential indicators that may hint at the presence of NTRK gene fusions
-
Event 1: Bambino Gesù Children’s Hospital, January 2020